-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly to Hold Clinical Data Presentations on Weight Loss Drugs in US

MT Newswires·11/15/2026 06:26:23
Listen to the news
06:26 AM EST, 11/15/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) will present its clinical data for trials that involve tirzepatide, orforglipron, retatrutide, and an eloralintide combo at the three-day ObesityWeek 2026 event in Washington, US. The pharmaceutical giant said Nov. 14 that the oral talks will cover the EloraTZP phase 2 study, the Triumph-1, Triumph-2, and Triumph-4 trials, as well as the phase 3 study for retatrutide and Zepbound. Additionally, the company will discuss its survey results for orforglipron and its exit interviews for the phase 2 study for eloralintide.